GCM
PRME icon

Graham Capital Management’s Prime Medicine PRME Stock Holding History

Graham Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.7K Sell
16,015
-98,665
-86% -$376K ﹤0.01% 1086
2025
Q4 		$398K Buy
+114,680
New +$510K 0.01% 725

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Graham Capital Management's PRME Position: Q1 2026 in Review

Graham Capital Management reduced its Prime Medicine (PRME) stake by 86% in Q1 2026, selling an estimated $376K and leaving 16,015 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Graham Capital Management first reported a position in PRME in Q4 2025 and has held it in 2 quarters since. The position peaked at $398K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Graham Capital Management held 16,015 shares of Prime Medicine worth $55.7K as of Q1 2026.
  • Graham Capital Management sold 98,665 Prime Medicine shares in Q1 2026, an estimated $376K.
  • Prime Medicine made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1086 holding.
  • Graham Capital Management first reported a position in Prime Medicine in Q4 2025 and has held it in 2 quarters since.
  • Graham Capital Management's Prime Medicine position peaked at $398K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.